Genetic alterations in chronic lymphocytic leukemia and plasma cell neoplasms – a practical guide to WHO HAEM5
Open Access
- 4 March 2024
- journal article
- research article
- Published by Walter de Gruyter GmbH in medizinische genetik
- Vol. 36 (1) , 47-57
Abstract
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO-HAEM5) provides a revised classification of lymphoid malignancies including chronic lymphocytic leukemia (CLL) and plasma cell myeloma/multiple myeloma (PCM/MM). For both diseases the descriptions of precursor states such as monoclonal B-cell lymphocytosis and monoclonal gammopathy of uncertain significance (MGUS) have been updated including a better risk stratification model. New insights on mutational landscapes and branching evolutionary pattern were embedded as diagnostic and prognostic factors, accompanied by a revised structure for the chapter of plasma cell neoplasms. Thus, the WHO-HAEM5 leads to practical improvements of biological and clinical relevance for pathologists, clinicians, geneticists and scientists in the field of lymphoid malignancies. The present review gives an overview on the landscape of genetic alterations in CLL and plasma cell neoplasms with a focus on their impact on classification and treatment.Keywords
This publication has 31 references indexed in Scilit:
- Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosisNature Communications, 2023
- Molecular map of chronic lymphocytic leukemia and its impact on outcomeNature Genetics, 2022
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid NeoplasmsLeukemia, 2022
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myelomaNature Communications, 2021
- Genomic landscape and chronological reconstruction of driver events in multiple myelomaNature Communications, 2019
- Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation projectCytometry Part B: Clinical Cytometry, 2018
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLLLeukemia, 2017
- Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendationsLeukemia, 2017
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient dataThe Lancet Oncology, 2016
- Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical managementLeukemia, 2010